TME Pharma NV
PAR:ALTME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TME Pharma NV
Income from Continuing Operations
TME Pharma NV
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TME Pharma NV
PAR:ALTME
|
Income from Continuing Operations
-€4.6m
|
CAGR 3-Years
37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Income from Continuing Operations
-€1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Income from Continuing Operations
€162.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Income from Continuing Operations
-€196.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Income from Continuing Operations
-€24.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Income from Continuing Operations
-€64.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
TME Pharma NV
Glance View
TME Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
See Also
What is TME Pharma NV's Income from Continuing Operations?
Income from Continuing Operations
-4.6m
EUR
Based on the financial report for Jun 30, 2025, TME Pharma NV's Income from Continuing Operations amounts to -4.6m EUR.
What is TME Pharma NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
1%
Over the last year, the Income from Continuing Operations growth was 28%. The average annual Income from Continuing Operations growth rates for TME Pharma NV have been 37% over the past three years , 1% over the past five years .
